WO2003010181A1 - PROCEDIMIENTO ESTEREOSELECTIVO PARA LA PRODUCCIÓN DE 6α-FLUORPREGNANOS E INTERMEDIOS - Google Patents
PROCEDIMIENTO ESTEREOSELECTIVO PARA LA PRODUCCIÓN DE 6α-FLUORPREGNANOS E INTERMEDIOS Download PDFInfo
- Publication number
- WO2003010181A1 WO2003010181A1 PCT/ES2002/000372 ES0200372W WO03010181A1 WO 2003010181 A1 WO2003010181 A1 WO 2003010181A1 ES 0200372 W ES0200372 W ES 0200372W WO 03010181 A1 WO03010181 A1 WO 03010181A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- alkyl
- group
- positions
- Prior art date
Links
- 0 CC*(C)*(C)N Chemical compound CC*(C)*(C)N 0.000 description 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Definitions
- the invention relates to a process of high stereoselectivity for the production of 6 ⁇ , -fluorpregnanos, which is carried out through new intermediates 3- (trisubstituted) silyloxy-pregna-3 > 5-dienes and in which the fluorine atom is introduced by the use of a fluorination agent of the N-fluorosulfonimide or N-fluorosulfonamide type.
- the 6 ⁇ -fluorpregnanos obtained are useful as synthesis intermediates for obtaining steroids that have therapeutic application as anti-inflammatory and anti-asthmatic agents.
- US Patent 3,178,412 describes a process for the introduction of the fluorine atom in position 6 also using 3-keto- ⁇ 4- steroids as substrates.
- the activation of position 6 is produced by the formation of an enol ether in position 3 that causes the displacement of the double bonds to positions 3,4 and 5,6.
- the intermediate formed reacts with perchloyl fluoride by introducing the fluorine in the 6 ⁇ position and restoring the 3-keto- ⁇ 4 system .
- US Patent 4,188,322 describes a process for the preparation of 6-halo pregnan functionalized with the ⁇ -epoxide group at positions 9.11. The activation of position 6 by formation of enol acetate using isopropenyl acetate as a reagent and the introduction of the fluorine atom using perchloyl fluoride is described. Spanish patent ES 2,091,100 describes a process for the preparation of 6 ⁇ , 9 ⁇ -difluorinated steroids derived from androstane with ester function at position 17.
- N-fluorbenzenesulfonimide leads to a 95: 5 ratio of isomeric mixture at 6 in favor of the beta isomer.
- fluorination reagents such as N-fluorpyridinium heptafluoroborate or Selectfluor® leads to epimeric mixtures in proportions from 9: 1 (in favor of the alpha isomer) to 0.8: 1 obtaining appreciable amounts of the 3-keto impurity -4,6-diona.
- the authors conclude that the reagent that results in better yields is Selectfluor ⁇ although practically without stereoselectivity.
- N-fluorobenzenesulfonimide has been described in the literature for the electrophilic flow of different substrates (Taylor et al., Tetrahedron 55 (1999) 12431), but has never been used successfully for the introduction of a fluorine atom in position 6 in steroids with high stereosectivity.
- reaction byproducts are produced, such as 4-fluoro steroids, 3-keto-4,6-dienones, D-homo derivatives and 6-chloro steroids
- perchloyl fluoride is a highly toxic and dangerous gas and must be handled with great care in manufacturing plants, with the risks that it entails for operators and goods.
- the invention faces the problem of providing a method of high stereoselectivity for the synthesis of 6 ⁇ -fluorpregnanos.
- the solution provided by this invention is based on the fact that the inventors have observed that the fluorination of a 3- (trisubstituted) silyloxy-pregna-3,5-diene with a fluorination agent of the N-fluorosulfonimide or N-fluorosulfonamide type leads to the Stereoselective introduction of fluoride in the. position 6 of the pregnan derivative, with a very high 6 / 6 ⁇ fluorine epimeric ratio and very low impurity production [see Examples 2-10 and compare with Reference Examples 1-7].
- an object of this invention is a stereoselective process for the production of 6 ⁇ -fluorpregnan which comprises reacting a 3- (trisubstituted) silyloxy-pregna-3,5-diene with a fluorination agent of the N -luorosulfonimide type or N-fluorosulfonamide.
- a further object of this invention is 3- (trisubstituted) silyloxy-pregna-3,5-dienes, and its use in the stereoselective synthesis of 6 ⁇ -fluorpregnan.
- Another additional object of this invention is a process for the synthesis of said 3- (trisubstituted) silyloxy-pregna-3,5-dienes which comprises reacting a pregna.no derivative and a silyl ethanesulfonalo trifluoro (trisubstituted).
- Another additional object of this invention is a procedure.
- Stereoselective for the production of 6 ⁇ -fluorpregnanos which comprises the silylation of a pregnan derivative with a silyl trifluoromethanesulfonate (trisubstituted) to obtain a 3- (trisubstituted) silyloxy-pregna-3,5-diene and the fluorination of this silylated derivative with a fluorination agent of the N-fluorosulfonimide or N-fl ⁇ orosulfonarnide type.
- the invention provides a process for the production of a 6-fluorpregnan, of general formula (I):
- Ri is OH, OCOR 2 , X, SO 3 R 3 , or a group (R 7 ) (R 8 ) (R 9 ) Si-, where X is halogen, R 2 and R 3 are C 1-6 alkyl or phenyl optionally substituted by C] alkyl. 4 , and R 7 , Rs and R9, the same or different, are Cj- ⁇ alkyl or phenyl optionally substituted by C ⁇ alkyl;
- the steroid ring C is:
- the steroid ring D is:
- P is H or CH 3 ( ⁇ or ⁇ configuration);
- R 5 ye same or different, are C ⁇ alkyl; and each P ', independently, is H, a hydroxyl protecting group or a group (R 7 ) (R s ) (R 9 ) Si-], where R 7 , R 8 and R 9 have the previously mentioned meaning;
- a fluorination agent selected from: (i) an N-fluorosulfonimide of the general formula (V)
- Rio and Rn are alkyl with one or more hydrogen atoms optionally substituted by halogen, or phenyl optionally substituted by C ⁇ alkyl;
- R is a C alkyl radical
- R J2 is phenyl optionally substituted by C ⁇ alkyl
- R] 3 is H, C ⁇ alkyl or phenyl optionally substituted by C ⁇ alkyl.
- C ⁇ or C ⁇ alkyl refers to a radical derived from a linear or branched alkane of 1 to 4, or 1 to 6, carbon atoms respectively.
- hydroxyl protecting group refers to a group capable of protecting the hydroxyl group or groups present in a compound so that it is possible to work with the protected compound without secondary reactions. in which said hydroxyl groups would be involved if they were not protected, for example, alkanoyl, tetrahydropyranyl and benzyl.
- a preferred class of compounds of formula (I) includes those compounds in which the dotted line between positions 1 and 2 represents a double bond.
- Another preferred class of compounds of formula. (I) includes those compounds in which Ri is hydroxyl, acetate, pivalate, propionate, mesylate or chlorine.
- Another preferred class of compounds of formula (1) includes those compounds that have a 9 ⁇ , 1 ⁇ -epoxy group in ring C or a double bond between positions 9 and 1 1 of ring C.
- Another preferred class of compounds of formula (I) includes those compounds in
- Another preferred class of compounds of formula (1) includes those compounds that contain an ⁇ OH group at position 17.
- Another preferred class of compounds of formula (I) includes those compounds in which R 5 and R ⁇ are simultaneously methyl .
- a particularly preferred class of compounds of formula (I) includes those compounds in which the dotted line between positions 1 and 2 represents a double bond, R) is hydroxyl, acetate, pivalate, propionalo, mesylate or chlorine, have a 9 ⁇ , 11 ⁇ -epoxy group in ring C, R 4 is ⁇ CH or ⁇ CH 3 and have an ⁇ OH group at position 17.
- Another particularly preferred class of compounds of formula (I) includes those compounds in which the dotted line between positions 1 and 2 represents a double bond, Rj is hydroxyl, acetate, pivalate, propionate, mesylate or chlorine, have a double it link between R, positions 9 and 1 1 is 0.CH 3 or ⁇ CH ⁇ and have an ⁇ OH group at position 17.
- the compounds of formula (I) can be used as synthesis intermediates of 6 ⁇ -fluorinated steroids with pharmacological activity, such as Diflorasone, Flumetasone, Flunisolide, Fluocinolone Acetonide, Fluocinonide, Flurandrenolide, Fluticasone, Halobetasol, Fluocortolone, Diflucortolone, Parametasone, etc., which have utility as anti-inflammatory and anti-asthmatic agents.
- pharmacological activity such as Diflorasone, Flumetasone, Flunisolide, Fluocinolone Acetonide, Fluocinonide, Flurandrenolide, Fluticasone, Halobetasol, Fluocortolone, Diflucortolone, Parametasone, etc.
- the reaction between the compound of formula (IV) and the electrophilic fluorination agent or reagent can be carried out in a solvent compatible with the reagents used, is that is, it is inert against them, preferably, in a halogenated organic solvent, such as methylene chloride, 1,2-dichloroethane or chloroform, although said reaction can also be carried out in other organic solvents such as aromatic hydrocarbons, acetonitrile or ethers .
- the fluorination reaction requires the presence of a base, preferably a weak organic nitrogen base such as triazole, aminotriazole, imidazole or pyridine.
- the reaction can be carried out at a temperature between -40 ° C and + 20 ° C, preferably between -10 ° C and O ° C.
- the compounds of formulas (V), (VI) and (Vil) are known and commercially available compounds or can be synthesized by methods described in the state of the art (see US Patent 5,478,964 and Davis et al. Tetrahedron Letters 1991, 32, 1631-4).
- the compounds of formula (IV) are new products, useful as intermediates in stereoselective synthesis, of 6 ⁇ -fluorpregna.nos and constitute a further object of this invention.
- the compounds of formula (IV) can be obtained by a process which comprises reacting a pregnan derivative of general formula (II)
- Rj is OH, OC0R 2 , X, SO 3 R 3 , or a group (R 7 ) (Rg) (R ⁇ >) Si-, where X is halogen, R 2 and R 3 are C ⁇ alkyl or phenyl optionally substituted by C ⁇ alkyl, and R 7 , Rs and Rs>, the same or different, are C ⁇ alkyl or phenyl optionally substituted by C ⁇ alkyl;
- the steroid ring C is:
- P is a protecting group of the hydroxyl group
- the steroid ring D is:
- R 5 and R ⁇ are C ⁇ alkyl; and each P ', independently, is H, a hydroxyl protecting group or a group
- a preferred class of compounds of formula (IV) includes those compounds in which the dotted line between positions 1 and 2 represents a double bond.
- Another preferred class of compounds of formula (IV) includes those compounds in which R] is acetate, pivalate, propionate or mesylate.
- Another preferred class of compounds of formula (IV) includes those compounds that have a 9 ⁇ , 1 ⁇ -epoxy group in ring C or a double bond between positions 9 and 11 of ring C.
- Another preferred class of compounds of formula (IV) includes those compounds in which R $ is CH 3 or ⁇ CH 3 .
- Another preferred class of compounds of formula (IV) includes those compounds that contain an ⁇ OH group at position 17.
- Another preferred class of compounds of formula (IV) includes those compounds in which R 5 and are simultaneously methyl.
- Another preferred class of compounds of formula (IV) includes those compounds in which two groups selected from R 7 , R * and R 9 are simultaneously methyl and the other is t-butyl, or in which R, R, and R 9 are simultaneously isopropyl.
- a particularly preferred class of compounds of formula (IV) includes those compounds in which the dotted line between positions 1 and 2 represents a double bond, R] is acetate, pivalate, propylate or mesylate, they have a group 9 ⁇ , ll ⁇ -epoxy in ring C, R4 is ⁇ CH 3 or ⁇ CH 3 , they have an ⁇ OH group at position 17, two groups selected from R 7 , R s and R 9 are simultaneously methyl and the other is t-butyl, or R 7 , Rs and R 9 are simultaneously isopropyl.
- Another particularly preferred class of compounds of formula (IV) includes those compounds in which the dotted line between positions 1 and 2 represents a double bond, Rj is acetate, pivalate, propionate or mesylate, has a double bond between positions 9 and 11, R 4 is ⁇ CH 3 or ⁇ CH 3 , they have an ⁇ OH group at position 37, two groups selected from R 7 , R 8 and R 9 are simultaneously methyl and the other is t-butyl, or R 7 , Rs and R 9 are simultaneously isopropyl.
- the reaction between the compound of formula (II) and (III) can be carried out in an anhydrous medium, in a conventional solvent, preferably, a halogenated solvent, such as dichloromethane or 1,2-dichloroethane, although other solvents such as acetonitrile or ethers, in the presence of a nitrogenous organic base, for example diisopropylethylamine, triethylamine, lutidine or collidine, preferably diisopropylethylamine, at a temperature between -20 C C and room temperature (15-25 ° C), preferably maintaining the reaction temperature between -10 ° C and 0 ° C.
- a nitrogenous organic base for example diisopropylethylamine, triethylamine, lutidine or collidine, preferably diisopropylethylamine
- silyl enol ether is very advantageous with respect to the formation of hydrated carbon ethers or enol esters described in the state of the art, regarding the minimization of secondary products and maximization of the reaction yield.
- the reagent used for the formation of the silyl enol ethers is a trialkyl or aryl silyl triflate, preferably, a trialkylsilyl triflate with long and / or branched chain hydrocarbon moieties, for example, t-butyldimethyl or triisopropyl, since they give rise to easily insulated, crystalline and identified compounds with conventional structural identification techniques.
- substituents also provides excellent stereoselectivity in the fluorination reaction.
- the most preferred reagents are tert-butyldi ethylsilyl triflate and triisopropylsilyl triflate, which are commercially available.
- the compounds of formula (11) can have a free hydroxyl functional group at positions 16 and / or 21, which can be silylated by the compound (111) to give rise to a compound of formula (IV) distilled or trisilylated at positions 3 and (16 and / or 21), which are also included within the scope of the compounds of formula (IV).
- These di- or trisilylated derivatives are obtained by silylation of compound (II) with hydroxy groups in positions 16 and / or 21 with an amount of silylating reagent (compound (III)) in a molar ratio compound (III): compound (II ) equal to or greater than .2 (to obtain the distilled derivative) or equal to or greater than 3 (to obtain the trisilylated derivative).
- the di- or trisilylated derivatives of the compound of formula (IV) can be obtained by silylation of the mono- or distilled compound (II) in positions 16 and / or 21 with said silylating reagent in the appropriate ratio.
- the invention also provides a process for the production of a 6-fluorpregnan (I) comprising reacting said compound of formula (II) with said compound of formula (III) to obtain said compound of formula (IV) which subsequently reacts with a electrophilic fluorination reagent of formula (V), (VI) or (Vil) to obtain the compound of formula (I).
- the conditions for performing each of the stages are those mentioned previously for each particular reaction.
- the intermediate (IV) obtained in the silylation stage can be isolated by conventional methods (for example, by crystallization) or, if desired, after the removal of water soluble contaminants, it can be used directly in the. fluorination reaction.
- An advantage of the process of obtaining the compound (I) by silylation of the compound (II) and subsequent fluorination of the intermediate (IV), according to the invention, is that the molar yield obtained in the transformation from the compound (II) to (1) ) in some cases exceeds 75% what is not achieved in the experimental conditions described in the state of the art.
- reaction mixture was precipitated on a solution of 400 mL of water and 28 mL of 30% hydrochloric acid cooled to 0 ° C. 150 L of methanol were charged and kept at 0 ° C for 1 hour. It was filtered and washed. 21 g of solid were obtained.
- the residue obtained in the distillation was mixed with 180 mL of methanol, 20 mL of water and 1.1 ml of pyridine under an inert atmosphere.
- the suspension was cooled to 0 ° C and then 9.4 g of N-fluoro-N-chloromethyl-triethylenediamine bis tetrafluoroborate was charged. At the end of the charge, it was kept at 0 ° C for 1 hour and filtered.
- the wet cake was suspended in 200 mL of water and a sufficient amount of 20% ammonium hydroxide was charged or to adjust the pH to 8. 2 g of sodium metabisulfite were charged and readjusted again to pH 8. It was filtered and Washed. 5 g of a product analyzed by HPLC were obtained under the following conditions:
- the temperature was raised to 10 ° C and 1,000 mL of water was charged. He stirred and decanted. The organic phase was distilled under vacuum and changed to 200 ml of acetonitrile. The resulting mixture was kept at 0 ° C for 1 hour and filtered and washed to obtain 122 g of the expected product.
- RN (CDC1 3 ): 400 MHz, ppm): 0.7 (s): 16-CH 3 ; 0.77 (s): 18-CH 3 ; 1.1 (s): 18-CH 3 ; 2.1 (s): CO-CH 3 ; 2.9 (s): H in position 11; 4.6, 5.05 (d, d): 2 H in position 21; 5.4 (dddd): H in position 6 ⁇ ; 6.2 (dd): H in position 2; 6.3 (t): H in position 4; 6.6 (dd): H in position 1.
- Example 8 9 ⁇ , ll ⁇ -epoxy-3,21-di (t-butyldimethylsilyloxy) -17 ⁇ -hydroxy-16 ⁇ -methylpregna-l, 3,5-trien-20-one
- Example 9 9 ⁇ , ll ⁇ -epoxy-3-t-but ⁇ ld ⁇ met ⁇ lsilyloxy-17 ⁇ , 2l-dihydroxy-l6 ⁇ -methylpregna- ⁇ , 3,5-trien-20-one 21-acetate
- Example 10 9 ⁇ , ll ⁇ -epoxy-3-t-butyldi ⁇ met ⁇ lsilyloxy-17 ⁇ , 21-dihydiOxy-16 ⁇ -methylpregna-l, 3 > 5-trien-20-one 21-mesylate
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Glass Compositions (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02751191A EP1422235B1 (en) | 2001-07-26 | 2002-07-24 | Stereoselective method of producing 6alpha-fluoropregnanes and intermediaries |
DE60215193T DE60215193T2 (de) | 2001-07-26 | 2002-07-24 | Stereoselektives verfahren zur herstellung von 6alpha-fluorpregnanen und zwischenprodukten |
AU2002355187A AU2002355187A1 (en) | 2001-07-26 | 2002-07-24 | Stereoselective method of producing 6alpha-fluoropregnanes and intermediaries |
JP2003515540A JP2004538294A (ja) | 2001-07-26 | 2002-07-24 | 6α−フルオロプレグナンの立体選択的製造方法および中間体 |
CA002455229A CA2455229A1 (en) | 2001-07-26 | 2002-07-24 | Stereoselective method of producing 6.alpha.-fluoropregnanes and intermediaries |
ES02751191T ES2274065T3 (es) | 2001-07-26 | 2002-07-24 | Procedimiento estereoselectivo para la produccion de 6alfa-fluorpregnados e intermedios. |
US10/764,915 US20040181055A1 (en) | 2001-07-26 | 2004-01-26 | Stereoselective process for the production of 6alpha-fluorpregnanes and intermediates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200101754A ES2184628B1 (es) | 2001-07-26 | 2001-07-26 | Procedimiento estereoselectivo para la produccion de 6alfa-fluorpregnanos intermedios. |
ESP200101754 | 2001-07-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/764,915 Continuation US20040181055A1 (en) | 2001-07-26 | 2004-01-26 | Stereoselective process for the production of 6alpha-fluorpregnanes and intermediates |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003010181A1 true WO2003010181A1 (es) | 2003-02-06 |
WO2003010181A8 WO2003010181A8 (es) | 2003-04-24 |
Family
ID=8498522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2002/000372 WO2003010181A1 (es) | 2001-07-26 | 2002-07-24 | PROCEDIMIENTO ESTEREOSELECTIVO PARA LA PRODUCCIÓN DE 6α-FLUORPREGNANOS E INTERMEDIOS |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040181055A1 (es) |
EP (1) | EP1422235B1 (es) |
JP (1) | JP2004538294A (es) |
AT (1) | ATE341561T1 (es) |
AU (1) | AU2002355187A1 (es) |
CA (1) | CA2455229A1 (es) |
DE (1) | DE60215193T2 (es) |
ES (2) | ES2184628B1 (es) |
WO (1) | WO2003010181A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101591482B1 (ko) * | 2008-05-28 | 2016-02-03 | 레베라겐 바이오파마 인코포레이티드 | 질환의 치료를 위한 NF-κB 의 비호르몬성 스테로이드 조절제 |
EP2556083A4 (en) | 2010-04-05 | 2013-12-04 | Validus Biopharma Inc | NONHORMONAL STEROID MODULATORS OF NF-KAPPA-B FOR DISEASE TREATMENT |
US10799514B2 (en) | 2015-06-29 | 2020-10-13 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease |
US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2002495A1 (fr) * | 1968-02-23 | 1969-10-17 | Hoffmann La Roche | Ethers silyliques de steroides et procede pour leur preparation |
US4036831A (en) * | 1975-10-28 | 1977-07-19 | Steroid Development Company Establishment | Trimethyl siloxane steroid intermediates |
US5086190A (en) * | 1989-05-12 | 1992-02-04 | Allied-Signal Inc. | Method of fluorinating by using N-fluoropyridinium pyridine heptafluorodiborate |
ES2091100T3 (es) * | 1993-02-05 | 1996-10-16 | Roussel Uclaf | Nuevo procedimiento de preparacion de esteroides 6alfa,9alfa-difluorados y nuevos productos intermedios obtenidos. |
EP1207166A2 (en) * | 2000-11-17 | 2002-05-22 | Farmabios S.r.l. | Process for the preparation of 6.alpha.-fluoro,9,11.beta.-epoxy-steroids |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2838499A (en) * | 1957-11-29 | 1958-06-10 | Upjohn Co | 6-fluoro steroids and process |
US3499016A (en) * | 1958-08-04 | 1970-03-03 | Upjohn Co | 6alpha-fluoro-16alpha-methyl derivatives of the pregnane series |
NL245860A (es) * | 1958-11-28 | |||
US3014938A (en) * | 1959-09-07 | 1961-12-26 | Syntex Sa | Preparation of 16, 21-diacetate derivative of cyclopentanophenanthrene compounds |
US3506650A (en) * | 1966-11-18 | 1970-04-14 | Warner Lambert Pharmaceutical | 1alpha-alkoxy-delta**4-3-keto pregnenes,3-enol ether thereof and process for their preparation |
US4188322A (en) * | 1978-04-28 | 1980-02-12 | Blasinachim S.P.A. | Process for the preparation of 6-halo-pregnanes |
DE3640709A1 (de) * | 1986-11-28 | 1988-06-09 | Schering Ag | Verfahren zur herstellung von 6(alpha),9(alpha)-difluor-11ss,17(alpha)-dihydroxy-16(alpha)-methyl-4-pregnen-3,20-dion und dessen derivate |
-
2001
- 2001-07-26 ES ES200101754A patent/ES2184628B1/es not_active Expired - Fee Related
-
2002
- 2002-07-24 EP EP02751191A patent/EP1422235B1/en not_active Expired - Lifetime
- 2002-07-24 CA CA002455229A patent/CA2455229A1/en not_active Abandoned
- 2002-07-24 DE DE60215193T patent/DE60215193T2/de not_active Expired - Lifetime
- 2002-07-24 JP JP2003515540A patent/JP2004538294A/ja active Pending
- 2002-07-24 WO PCT/ES2002/000372 patent/WO2003010181A1/es active IP Right Grant
- 2002-07-24 AU AU2002355187A patent/AU2002355187A1/en not_active Abandoned
- 2002-07-24 AT AT02751191T patent/ATE341561T1/de not_active IP Right Cessation
- 2002-07-24 ES ES02751191T patent/ES2274065T3/es not_active Expired - Lifetime
-
2004
- 2004-01-26 US US10/764,915 patent/US20040181055A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2002495A1 (fr) * | 1968-02-23 | 1969-10-17 | Hoffmann La Roche | Ethers silyliques de steroides et procede pour leur preparation |
US4036831A (en) * | 1975-10-28 | 1977-07-19 | Steroid Development Company Establishment | Trimethyl siloxane steroid intermediates |
US5086190A (en) * | 1989-05-12 | 1992-02-04 | Allied-Signal Inc. | Method of fluorinating by using N-fluoropyridinium pyridine heptafluorodiborate |
ES2091100T3 (es) * | 1993-02-05 | 1996-10-16 | Roussel Uclaf | Nuevo procedimiento de preparacion de esteroides 6alfa,9alfa-difluorados y nuevos productos intermedios obtenidos. |
EP1207166A2 (en) * | 2000-11-17 | 2002-05-22 | Farmabios S.r.l. | Process for the preparation of 6.alpha.-fluoro,9,11.beta.-epoxy-steroids |
Non-Patent Citations (3)
Title |
---|
PROCOPIOU P.A. ET AL: "An extremely powerful activation reaction of alcohols with anhydrides catalyzed by trimethylsilyl trifluoromethanesulfonate", J. ORG. CHEM., vol. 63, no. 7, 1998, pages 2342 - 2347, XP002976824 * |
TAYLOR S.D. ET AL: "Recent advances in electrophilic fluorination", TETRAHEDRON, vol. 55, no. 43, 1999, pages 12431 - 12477, XP004179337 * |
THOMAS M.G. ET AL: "The synthesis of A- and B-ring fluorinated analogues of cholesterol", J. CHEM. SOC., PERKIN TRANS. 1, vol. 21, 1999, pages 3191 - 3198, XP002976823 * |
Also Published As
Publication number | Publication date |
---|---|
ES2274065T3 (es) | 2007-05-16 |
ES2184628B1 (es) | 2005-02-01 |
JP2004538294A (ja) | 2004-12-24 |
US20040181055A1 (en) | 2004-09-16 |
ES2184628A1 (es) | 2003-04-01 |
DE60215193T2 (de) | 2007-08-23 |
ATE341561T1 (de) | 2006-10-15 |
DE60215193D1 (de) | 2006-11-16 |
AU2002355187A1 (en) | 2003-02-17 |
EP1422235A1 (en) | 2004-05-26 |
CA2455229A1 (en) | 2003-02-06 |
WO2003010181A8 (es) | 2003-04-24 |
EP1422235B1 (en) | 2006-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU188067B (en) | Process for preparing delta 17/20/21-substituted steroids | |
EP0073026B1 (en) | 17,17-bis(substituted thio)-3-ketoandrostenes and pharmaceutical compositions | |
WO2008035066A2 (en) | Processes for the preparation of ciclesonide and its crystal form | |
IE41545B1 (en) | Fluorination process and novel fluoro steroids | |
ES2274065T3 (es) | Procedimiento estereoselectivo para la produccion de 6alfa-fluorpregnados e intermedios. | |
EP1242444A1 (en) | Process for preparing 17alpha-acetoxy-11beta- 4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates | |
EP0112758B1 (en) | 16-ketoandrostene-17-dithioketals | |
US4990612A (en) | 16α-methylation process | |
AU646342B2 (en) | New substituted 16-methyl steroid derivatives of pregna-1,4-diene-3,20-dione, their preparation, their use in the preparation of 16-methylene steroids and new intermediates | |
EP0165037B1 (en) | 16 alpha-methyl steroids and their preparation | |
ES2342274T3 (es) | Reduccion estereoespecifica de sapogen-3-onas. | |
EP0308412B1 (en) | 16$g(a)-METHYLATION PROCESS | |
CA1244404A (en) | 17- (substituted thio)-17-(substituted dithio)androstenes | |
IE922042A1 (en) | New substituted 16-methyl steroid derivatives of¹pregna-1,4-diene-3,20-dione, their preparation, their use in¹the preparation of 16-methylene steroids and new¹intermediates | |
HU180520B (en) | Process for producing 17-alpha-alkinyl derivatives of 17-beta-hydroxy-andorst-4-ene-3-one | |
HU187551B (en) | Process for preparing androstene-17-thiones and -dithioketals | |
US4278669A (en) | 3-Oxo-4-halo-16β-methylandrost-4-ene 17β-carboxylic acids and esters | |
US4284827A (en) | Process to prepare metalated olefins | |
GB2123425A (en) | Androstene-17-diethioketals | |
HU184729B (en) | Process for the preparation of metal-olefine compounds | |
CA1058161A (en) | 3,20-DIKETOPREGNENES HAVING AN 11.beta.-ACETAL GROUP AND DERIVATIVES THEREOF | |
US3980680A (en) | Process for the preparation of 21-desoxy-17-acyloxy-4-pregnenes and of 21-iodo-21-desoxy-17-acyl oxy-4-pregnene intermediates useful therein | |
CS209915B2 (en) | Method of making the 4-halogenpregna-1,4-dien-3,20-dions | |
CS208494B2 (en) | Method of making the alcylesters of the 4-halogen-3-oxoandrosta-1,4-dien-17 beta-cyrboxyl acid | |
SE191715C1 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CH CN CU CZ DE DK EE ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MK MN MW MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 06/2003 UNDER (74) REPLACE "ZUAZU ARALUZE, ALEXANDER" BY "ZUAZO ARALUZE, ALEXANDER";UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003515540 Country of ref document: JP Ref document number: 10764915 Country of ref document: US Ref document number: 2455229 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002751191 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002751191 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002751191 Country of ref document: EP |